Heidelberg Pharma AG (FRA:HPHA)

Germany flag Germany · Delayed Price · Currency is EUR
2.980
-0.100 (-3.25%)
Last updated: Oct 17, 2025, 5:36 PM CET
-3.25%
Market Cap136.55M
Revenue (ttm)3.04M
Net Income (ttm)-26.18M
Shares Outn/a
EPS (ttm)-0.55
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,910
Average Volume2,441
Open3.020
Previous Close3.080
Day's Range2.980 - 3.020
52-Week Range2.110 - 5.400
Betan/a
RSI33.00
Earnings DateOct 10, 2025

About Heidelberg Pharma AG

Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, the United States, and internationally. Its lead product candidates include HDP-101, an anti-BCMA antibody, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company develops HDP-102, an antibody and the compound Amanitin, which has completed preclinical development for the treatment of non-Hodgkin lymphoma; HDP-103, a proprietary ATAC candidate to treat metastatic cas... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1997
Employees 105
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol HPHA
Full Company Profile

Financial Performance

In 2024, Heidelberg Pharma AG's revenue was 6.85 million, a decrease of -30.53% compared to the previous year's 9.86 million. Losses were -19.38 million, -4.74% less than in 2023.

Financial Statements

News

EQS-NVR: Heidelberg Pharma AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

EQS Total Voting Rights Announcement: Heidelberg Pharma AG / Total Voting Rights Announcement Heidelberg Pharma AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with...

8 days ago - Wallstreet:Online

Heidelberg Pharma's Bold Moves in 2025's First 9 Months

Heidelberg Pharma is navigating a pivotal phase, honing in on its promising ADC candidate, HDP-101, amidst strategic shifts and financial recalibrations. Jetzt den vollständigen Artikel lesen

13 days ago - Wallstreet:Online

EQS-News: Heidelberg Pharma Reports on the First Nine Months of Financial Year 2025

EQS-News: Heidelberg Pharma AG / Key word(s): Quarterly / Interim Statement Heidelberg Pharma Reports on the First Nine Months of Financial Year 2025 09.10.2025 / 07:03 CET/CEST The issuer is solely r...

13 days ago - Wallstreet:Online

Heidelberg Pharma AG Boosts Outlook: Exciting New Guidance Revealed!

Heidelberg Pharma AG is steering its financial ship with precision, honing in on cost-saving strategies for 2025. The company has revised its sales and income expectations to a more conservative EUR 7...

15 days ago - Wallstreet:Online

EQS-Adhoc: Heidelberg Pharma AG Announces Updated Guidance

EQS-Ad-hoc: Heidelberg Pharma AG / Key word(s): Change in Forecast Heidelberg Pharma AG Announces Updated Guidance 06-Oct-2025 / 15:58 CET/CEST Disclosure of an inside information acc. to Article 17 M...

15 days ago - Wallstreet:Online

EQS-News: Heidelberg Pharma Advances to Cohort 9 in Phase I/IIa Trial of Lead ATAC Candidate HDP-101 in Multiple Myeloma

EQS-News: Heidelberg Pharma AG / Key word(s): Study results Heidelberg Pharma Advances to Cohort 9 in Phase I/IIa Trial of Lead ATAC Candidate HDP-101 in Multiple Myeloma 25.09.2025 / 13:17 CET/CEST T...

26 days ago - Wallstreet:Online

EQS-News: Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Payment

EQS-News: Heidelberg Pharma AG / Key word(s): Strategic Company Decision Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Paym...

27 days ago - Wallstreet:Online

EQS-Adhoc: Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Payment

EQS-Ad-hoc: Heidelberg Pharma AG / Key word(s): Strategic Company Decision Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Pa...

27 days ago - Wallstreet:Online

EQS-News: Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2025

EQS-News: Heidelberg Pharma AG / Key word(s): Conference Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 20...

6 weeks ago - Wallstreet:Online

EQS-Adhoc: Heidelberg Pharma’s Partner Telix Pharmaceuticals Gives Regulatory Update for its Imaging Agent TLX250-CDx

EQS-Ad-hoc: Heidelberg Pharma AG / Key word(s): Financing Heidelberg Pharma’s Partner Telix Pharmaceuticals Gives Regulatory Update for its Imaging Agent TLX250-CDx 28-Aug-2025 / 03:50 CET/CEST Disclo...

7 weeks ago - Wallstreet:Online

EQS-NVR: Heidelberg Pharma AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

EQS Total Voting Rights Announcement: Heidelberg Pharma AG / Total Voting Rights Announcement Heidelberg Pharma AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with...

2 months ago - Wallstreet:Online

EQS-DD: Heidelberg Pharma AG: Prof. Dr. Andreas Pahl, Acquisition of 90,000 shares through the exercise of 90,000 stock options under the 2011 stock option program (tranche 2; issue 2016) for ...

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 24.07.2025 / 14:23 CET/CEST The issuer is solely responsi...

3 months ago - Wallstreet:Online

EQS-News: Heidelberg Pharma Reports on First Half-Year 2025 and the Positive Course of Business

EQS-News: Heidelberg Pharma AG / Key word(s): Half Year Report Heidelberg Pharma Reports on First Half-Year 2025 and the Positive Course of Business 10.07.2025 / 07:03 CET/CEST The issuer is solely re...

3 months ago - Wallstreet:Online

EQS-News: Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting 2025 and New Supervisory Board

EQS-News: Heidelberg Pharma AG / Key word(s): AGM/EGM Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting 2025 and New Supervisory Board 15.05.2025 / 14:31 CET/CEST The iss...

5 months ago - Wallstreet:Online

EQS-News: Heidelberg Pharma to Present Promising New Clinical Data on its Lead ATAC Candidate HDP-101 at EHA 2025

EQS-News: Heidelberg Pharma AG / Key word(s): Conference Heidelberg Pharma to Present Promising New Clinical Data on its Lead ATAC Candidate HDP-101 at EHA 2025 14.05.2025 / 18:40 CET/CEST The issuer ...

5 months ago - Wallstreet:Online

EQS-News: Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2025

EQS-News: Heidelberg Pharma AG / Key word(s): Quarterly / Interim Statement Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2025 24.04.2025 / 07:16 CET/CEST The iss...

6 months ago - Wallstreet:Online

EQS-News: Heidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025

EQS-News: Heidelberg Pharma AG / Key word(s): Conference Heidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025 26.03.2025 / 09:23 CET/CEST The issuer is solel...

7 months ago - Wallstreet:Online